Non-invasive Imaging in the Pharmaceutical Industry

  • Sally-Ann Emmas
  • Paul D. Hockings
  • John C. Waterton
Chapter
First Online:

Abstract

The pharmaceutical industry faces an existential threat. Over recent years, the time and costs to get a new drug to market have increased to unsustainable levels whilst productivity is declining. It is critical to both improve efficiency of the drug discovery and development process and to increase success rates, with better predictivity from preclinical to clinical investigation (Kola 2008). Imaging provides unique tools to improve efficiency, predictivity and probability of success.

Keywords

Drug Discovery Drug Discovery Process Follow Drug Administration Increase Success Rate Existential Threat 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Atkinson Jr AJ, Colburn WA, DeGruttola VG, DeMets DL, Downing GJ, Hoth DF, Oates JA, Peck CC, Schooley RT, Spilker BA, Woodcock J, Zeger SL. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.CrossRefGoogle Scholar
  2. Beckmann N, et al. Pulmonary edema induced by allergen challenge in the rat: non-invasive assessment by magnetic resonance imaging. Magn Reson Med. 2001;45:88–95.CrossRefPubMedGoogle Scholar
  3. Bell JP, Chevalier E, Tessier J, Bradley D, Mather ME, Young SS, Bahl AK, Escott KJ, Young A. Use of magnetic resonance imaging (MRI) to track big endothelin-1-induced edema in the rat lung. Am J Respir Crit Care Med. 2007;175:A533.Google Scholar
  4. Bowyer J, Heapy CG, Flannelly JK, Waterton JC, Maciewicz RA. Evaluation of a magnetic resonance biomarker of osteoarthritis disease progression: doxycycline slows tibial cartilage loss in the Dunkin Hartley guinea pig. Int J Exp Pathol. 2009;90:174–81.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Bradley DP, Tessier JJ, Ashton SE, Waterton JC, Wilson Z, Worthington PL, Ryan AJ. Correlation of MRI biomarkers with tumor necrosis in Hras5 tumor xenograft in athymic rats. Neoplasia. 2007;9:382–91.CrossRefPubMedPubMedCentralGoogle Scholar
  6. Cove-Smith L, Woodhouse N, Hargreaves A, Kirk J, Smith S, Price SA, Galvin M, Betts CJ, Brocklehurst S, Backen A, Radford J, Linton K, Roberts RA, Schmitt M, Dive C, Tugwood JD, Hockings PD, Mellor HR. An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity. Toxicol Sci. 2014;140:3–15.CrossRefPubMedGoogle Scholar
  7. Erondu N, et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab. 2006;4:260–2.CrossRefGoogle Scholar
  8. Evelhoch JL, LoRusso PM, He Z, DelProposto Z, Polin L, Corbett TH, Langmuir P, Wheeler C, Stone A, Leadbetter J, Ryan AJ, Blakey DC, Waterton JC. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res. 2004;10:3650–7.CrossRefPubMedGoogle Scholar
  9. Fong TM. Development of anti-obesity agents: drugs that target neuropeptide and neurotransmitter systems. Expert Opin Investig Drugs. 2008;17:321–5.CrossRefPubMedGoogle Scholar
  10. Keen HG, Ricketts SA, Maynard J, Logie A, Odedra SAM, Wedge SR, Guichard SM. Examining changes in [18F]FDG and [18F]FLT uptake in U87-MG glioma xenografts as early response biomarkers to treatment with the dual mTOR1/2 inhibitor AZD8055. Mol Imaging Biol. 2014;16:421–30.CrossRefPubMedGoogle Scholar
  11. Kola I. The state of innovation in drug development. Clin Pharmacol Ther. 2008;83:227–30.CrossRefPubMedGoogle Scholar
  12. Hockings PD. Magnetic resonance imaging in pharmaceutical safety assessment. In: Vogel HG, Hock FJ, Maas J, Mayer D, editors. Drug discovery and evaluation: safety and pharmacokinetic assays. Heidelberg: Springer; 2006. p. 385–93.CrossRefGoogle Scholar
  13. Holt MP, Ju C. Mechanisms of drug-induced liver injury. AAPS J. 2006;8:E48–54.CrossRefPubMedPubMedCentralGoogle Scholar
  14. Hopkins AL, Groom CR. Opinion: the druggable genome. Nat Rev Drug Discov. 2002;1:727–30.CrossRefPubMedGoogle Scholar
  15. Hultin L, Hyberg G, von Mentzer B, Martinez V. Effects of corticotropin releasing factor and urocortins on gastric emptying and motility in rats assessed by functional X-ray. In: XII European Symposium on Neurogastroenterology and Motility. Cambridge; 2004. p. T150.Google Scholar
  16. Liachenko S, Ramu J, Konak T, Paule MG, Hanig J. Quantitative assessment of MRI T2 response to kainic acid neurotoxicity in rats in vivo. Toxicol Sci. 2015;46:183–91.CrossRefGoogle Scholar
  17. McIntyre DJ, Robinson SP, Howe FA, Griffiths JR, Ryan AJ, Blakey DC, Peers IS, Waterton JC. Single dose of the antivascular agent, ZD6126 (N-acetylcolchinol-Ophosphate), reduces perfusion for at least 96 hours in the GH3 prolactinoma rat tumor model. Neoplasia. 2004;6:150–7.CrossRefPubMedPubMedCentralGoogle Scholar
  18. McLarty K, Cornelissen B, Cai Z, Scollard DA, Costantini DL, Done SJ, Reilly RM. Micro-SPECT/CT with 111In-DTPA-Pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDAMB-361 HUMAN breast cancer xenografts. J Nucl Med. 2009;50:1340–8.CrossRefPubMedGoogle Scholar
  19. Olsson LE, et al. 1H and hyperpolarized 3He MR imaging of mouse with LPS-induced inflammation. J Magn Reson Imaging. 2009;29:977–81.CrossRefPubMedGoogle Scholar
  20. Tessier JJ, Bowyer J, Brownrigg NJ, Peers IS, Westwood FR, Waterton JC, Maciewicz RA. Characterisation of the guinea pig model of osteoarthritis by in vivo three-dimensional magnetic resonance imaging. Osteoarthritis Cartilage. 2003;11:845–53.CrossRefPubMedGoogle Scholar
  21. Ulloa JL, Stahl S, Yates J, Woodhouse N, Kenna JG, Jones HB, Waterton JC, Hockings PD. Assessment of gadoxetate DCE-MRI as a biomarker of hepatobiliary transporter inhibition. NMR Biomed. 2013;26:1258–70.CrossRefPubMedPubMedCentralGoogle Scholar
  22. Waterton JC, Middleton BJ, Pickford R, Allott CP, Checkley D, Keith RA. Reduced animal use in efficacy testing in disease models with use of sequential experimental designs. Dev Anim Vet Sci. 2000;31:737–45.Google Scholar
  23. Williams RE, Prior M, Bachelard HS, Waterton JC, Checkley D, Lock EA. MRI studies of the neurotoxic effects of L-2-chloropropionic acid on rat brain. Magn Reson Imaging. 2001;19:133–42.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Sally-Ann Emmas
    • 1
    • 2
  • Paul D. Hockings
    • 3
    • 4
  • John C. Waterton
    • 5
    • 6
  1. 1.Personalised Healthcare and Biomarkers, AstraZenecaMacclesfieldUK
  2. 2.Alderley ImagingCheshireUK
  3. 3.MedTech WestChalmers University of TechnologyGothenburgSweden
  4. 4.Antaros MedicalBioVenture HubMölndalSweden
  5. 5.Biomedical Imaging InstituteManchester Academic Health Sciences Centre, University of ManchesterManchesterUK
  6. 6.Alderley Imaging LtdCheshireUK

Personalised recommendations